VIZAMYL 400 MBq/mL solution for injection clinical trials

Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis

This study is looking at a special scan called a PET scan to see how a new tracer (a tiny amount of a radioactive substance) called Vizamyl works. We want to see how much of it is taken up by the heart in people with different types of cardiac amyloidosis.